May 6 (Reuters) - Gossamer Bio said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions.

Gossamer is to receive $160 million development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal. (Reporting by Christy Santhosh; Editing by Vijay Kishore)